Aspirin resistance: an evaluation of current evidence and measurement methods (Q28183220)

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Europe PubMed Central

title

Aspirin resistance: an evaluation of current evidence and measurement methods (English)

0 references

1 reference

Christopher P Martin

1

0 references

Robert L Talbert

series ordinal

2

0 references

language of work or name

English

0 references

publication date

July 2005

0 references

published in

Pharmacotherapy

0 references

volume

25

0 references

issue

7

0 references

page(s)

942-53

0 references

cites work

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Towards a definition of aspirin resistance: a typological approach

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Genetic variation in cyclooxygenase 1: effects on response to aspirin

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Platelet function testing in cardiovascular diseases

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin resistance: a revival of platelet aggregation tests?

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin Dosage and Thromboxane Synthesis in Patients with Vascular Disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study

21 April 2017

1 reference

https://api.crossref.org/works/10.1592/PHCO.2005.25.7.942

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

21 April 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

A meta‐analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Pharmacokinetic optimisation of the treatment of embolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Laboratory investigation of platelet function: a review of methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Estimated rate of thromboxane secretion into the circulation of normal humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Variability in platelet responsiveness to clopidogrel among 544 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942

Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2005.25.7.942